Skip to content

Specific molecular imaging of DX600 labeled by PET radionuclide targeting ACE2 in patients

Specific molecular imaging of DX600 labeled by PET radionuclide targeting ACE2 in patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000033675
Enrollment
Unknown
Registered
2020-06-08
Start date
2020-06-08
Completion date
Unknown
Last updated
2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumors

Interventions

Gold Standard:Compared with 18F-FDG PET/CT.
Gemini&#32
TF16&#32
or&#32
biometric&#32
m-ct&#32
flow&#32
CT&#32
to&#32
the&#32
and&#32
trunk,&#32

Sponsors

Beijing Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-75 years, male and female unlimited; 2. Patients with ECoG score of 0 or 1; 3. Patients with high expression of ACE2 in colorectal cancer, renal cancer, pancreatic cancer, gastric cancer, liver cancer, lung cancer, brain tumor or suspected tumor who are to undergo pathological biopsy or tumor surgery in the near future (within 2 months); 4. Patients with 18F-FDG PET / CT results as baseline assessment.

Exclusion criteria

Exclusion criteria: 1. Patients with severe abnormal liver and kidney function; 2. Pregnant and lactating women during pregnancy preparation; 3. Patients who can't lie flat for half an hour; 4. Patients with claustrophobia or other mental diseases; 5. Patients who refused to join the clinical study.

Design outcomes

Primary

MeasureTime frame
SUV;SEN, SPE, ACC, AUC of ROC;

Countries

China

Contacts

Public ContactZhu Hua

Nuclear Medicine Department,Third floor, Outpatient Building, Beijing Cancer Hospital

zhuhuananjing@163.com+86 10-88196495

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 22, 2026